Steffen Goletz | Professor, Department of Biotechnology and Biomedicine
Danish Technical University

Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University

PhD, Professor, Head of RG Biotherapeutic Glycoengineering & Immunology, DTU Bioengineering, Technical University of Denmark. Focus on novel bi- and multispecific antibody and cell-based therapeutics in immunooncology and infectious diseases. After early career in academic research, e.g. MDC in Berlin and MRC in Cambridge, SG founded, lead and matured Biotech companies successfully as CEO and CSO over >17 years before joining DTU as professor, Deputy Head of the Department and Head of Innovation & Entrepreneurship. Extensive experience in Strategic & Corporate Development, Investor Financing & Licensing, R&D, patenting and GMP manufacturing, incl. Early Research & Discovery, Preclinical Development, Process Development, Toxicology of Biopharmaceuticals, and Clinical Development and from FIM to larger PhIIb Studies. Heading R&D of biotherapeutic antibodies and proteins, complex antibody engineering, phage display, cellular and molecular glycoengineering, mammalian production cell system engineering, USP and DSP production process development. Heading GMP-production, preclinical and clinical development.

Appearances:



Festival of Biologics Day 1 @ 15:00

Robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds

Festival of Biologics Day 3 @ 11:30

Title TBA

last published: 13/Jun/25 16:06 GMT

back to speakers

Get involved at Festival of Biologics Basel 2025

 

 

TO SPONSOR


Derek Cavanagh

Derek.Cavanagh@terrapinn.com

 

Jack Bebb
Jack.Bebb@terrapinn.com

 

TO SPEAK


Jack Beard
Jack.Beard@terrapinn.com

 

MARKETING & PRESS


Ollie McDaid

ollie.mcdaid@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.